Program
VXA-G1.1-NN
A development code.
Its studies are mostly in Caliciviridae Infections, led by Vaxart.
Furthest: phase 2, since Apr 19, 20216 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vaxart | 60 open or running | phase 2since Apr 19, 2021 | Mar 28, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2019First study: phase 1 study in Caliciviridae InfectionsFirst studyNCT03897309 · 86 enrolled · United States
- Apr 19, 2021Phase 2 study in Caliciviridae InfectionsNCT04875676 · 30 enrolled · United States
- Jan 18, 2022Phase 1 study in Caliciviridae InfectionsNCT05213728 · 8 enrolled · United States
- Jan 25, 2022Phase 2 study in Caliciviridae InfectionsNCT05212168 · 165 enrolled · United States
- Apr 17, 2025Phase 1 study in Caliciviridae InfectionsNCT06944717 · 60 enrolled · United States
- Nov 19, 2025Phase 1 study in Caliciviridae InfectionsNCT07254728 · 76 enrolled · South Africa
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07254728Caliciviridae Infections · South Africa | 1 | Completed | Dec 13, 2024 | 76 |
| NCT06944717Caliciviridae Infections · United States | 1 | Completed | Apr 14, 2026 | 60 |
| NCT05212168Caliciviridae Infections · United States | 2 | Completed | Apr 13, 2023 | 165 |
| NCT05213728Caliciviridae Infections · United States | 1 | Completed | Feb 1, 2022 | 8 |
| NCT04875676Caliciviridae Infections · United States | 2 | Completed | Oct 30, 2021 | 30 |
| NCT03897309Caliciviridae Infections · United States | 1 | Completed | Jan 15, 2021 | 86 |
How it is read
Names in the registry
- “VXA-G1.1-NN”, 6 entries
Codes read as this program: VXAG11NN.
Conditions, from the studies’ own filings
- Caliciviridae Infections, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.